Sai Life Sciences · NSE: SAILIFE · BSE: 544306
Q2 FY26 results · Jul–Sep 2025
Sai Life Sciences reported revenue from operations of ₹537.47 crore and net profit of ₹83.84 crore for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 537.47 | — | — | 496.42 | +8.3% |
| Other income | 15.32 | — | — | 9.90 | +54.7% |
| Total income | 552.79 | — | — | 506.32 | +9.2% |
| Profit before tax | 112.05 | — | — | 80.75 | +38.8% |
| Net profit for the period | 83.84 | — | — | 60.45 | +38.7% |
| EPS, basic (₹) | 4.01 | — | — | 2.90 | +38.3% |
| Net margin (%) | 15.6 | — | 12.2 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 526.67 | — | — | 483.04 | +9.0% |
| Other income | 14.93 | — | — | 10.01 | +49.2% |
| Total income | 541.60 | — | — | 493.04 | +9.8% |
| Profit before tax | 110.87 | — | — | 77.98 | +42.2% |
| Net profit for the period | 82.95 | — | — | 58.37 | +42.1% |
| EPS, basic (₹) | 3.97 | — | — | 2.80 | +41.8% |
| Net margin (%) | 15.7 | — | 12.1 |
Consolidated
- Filed with BSE
- 06 Nov 2025, 20:34 IST
- Board meeting
- 06 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Nov 2025, 20:34 IST
- Board meeting
- 06 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE